These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Author: Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH.
    Journal: Biochem Biophys Res Commun; 2006 Dec 08; 351(1):99-105. PubMed ID: 17052691.
    Abstract:
    The crucial role of p38 mitogen-activated protein kinase for osteoclast differentiation has been suggested from studies with specific pharmacological inhibitors and dominant-negative forms of p38. However, the targets through which p38 regulates osteoclast differentiation have not been clearly revealed. Here, we show that inhibition of p38 activity with SB203580 reduced osteoclastogenesis from primary precursor cells, with concomitant suppression in the induction of both c-Fos and nuclear factor of activated T cells (NFAT) c1 by receptor activator of nuclear factor kappaB ligand (RANKL), the key osteoclast differentiation factor. Overexpression of dominant-negative forms of p38 upstream kinases MKK3 and MKK6 elicited similar reduction in RANKL-stimulated elevation of c-Fos and NFATc1. Interestingly, overexpression of c-Fos restored RANKL-induced osteoclast differentiation from and NFATc1 expression in SB203580-treated precursor cells. Our results demonstrate a previously unknown function of the p38 pathway in up-regulating c-Fos and NFATc1 expression during RANKL-induced osteoclastogenesis.
    [Abstract] [Full Text] [Related] [New Search]